As the percentage of Americans taking Ozempic and other similar GLP-1 drugs increases, the way Americans are eating, as well as spending their time and money, is changing, The Washington Post reported.

“In just over a year, the percentage of U.S. adults taking drugs such as Ozempic, Wegovy, Mounjaro and Zepbound more than doubled to 12.4%, according to Gallup. The survey also reported that the obesity rate fell from almost 40% in 2022 to 37% in 2025. Some companies are already responding by acquiring health food brands, renovating hotel gyms and changing lunch menus,” the outlet wrote.

At pharmacies, the research found that sales of supplements and vitamin-rich beauty products have surged, and GLP-1 users are buying more supplements such as electrolytes, hair-growth products and anti-nausea medications.

At grocery stores, GLP-1 users reduced their spending by 10% over a year across 100 categories including groceries, quick-service restaurants and tobacco, compared with non-GLP-1 households, according to the research company Numerator.

GLP-1 users have also cut back on alcohol. “Studies show that GLP-1 drugs can suppress alcohol cravings among heavy drinkers. Users spent 14.5% less in the category after starting the treatment, while nonalcoholic wine and beer purchases among the group ballooned by 1,158% and 935%, respectively, according to NIQ. Meanwhile, high-protein drinks and probiotic soda brands that promote gut health—which are also popular among non-GLP-1 users—are seeing significant growth,” the Post wrote.

Grocery data indicates that consumers taking GLP-1s are spending more time cooking at home instead of dining out. In the six months after starting the medications, users reduced their spending on dining out by 8.6%, according to Numerator and Cornell University.

In October, Costco announced it would begin selling weight-loss drugs in the United States to Costco members with a prescription. The price is $499 out of pocket for a four-week supply of medication.

Read more about how to attract GLP-1 consumers in the June 2025 issue of NACS Magazine article “Targeting the GLP-1 Shopper.”